📈 69% of S&P 500 stocks beating the index - a historic record! Pick the best ones with AI.See top stocks

Biocon Biologics Clinches Seventh Consecutive Asia IP Elite Recognition

Published 15-12-2023, 11:50 am
© Reuters.
BION
-

By Aayush Khanna

Biocon Biologics Limited, a subsidiary of Biocon Limited (NS:BION), has once again secured the prestigious title of Asia IP Elite for 2023, as announced by IAM (Intellectual Asset Management), the world's largest IP publication. This recognition is reserved for a select group of Asia-based corporations and research institutions that lead in intellectual property value creation.

Having debuted on this prestigious list in 2019, Biocon Biologics is marking its seventh consecutive year of recognition, affirming its robust IP management and consistent creation of IP value. Notably, Biocon Biologics is one of the three pharmaceutical companies from India featured on this year's list, and its IPR team has been acclaimed as the 'Healthcare and Biotechnology Team of the Year' from Asia for 2023.

Shreehas Tambe, CEO & Managing Director of Biocon Biologics, expressed honor in receiving this award for the seventh time, acknowledging it as a testament to their commitment to innovation and intellectual capital creation. He commended the IP team for their remarkable achievement and emphasized Biocon Biologics' dedication to utilizing science for affordable innovation globally.

Biocon Biologics strategically employs its in-house IP capabilities to facilitate early entry of biosimilar products, addressing patients' needs for affordable therapy on a global scale.

The selection criteria for the Asia IP Elite encompass placing IP strategy at the core of business, obtaining significant and ongoing value from intellectual property, senior management's understanding of the strategic importance of IP, and a continual reassessment and improvement of the IP strategy to capitalize on market developments.

In 2023, 88 entities from India, China, Japan, South Korea, Malaysia, Thailand, Taiwan, Australia, New Zealand, and Singapore were featured on the list. IAM recognized Biocon Biologics' IPR team as the 'Healthcare and Biotechnology Team of the Year,' acknowledging their noteworthy contributions based on publicly available information and market feedback.

-----------------------------------------------------------------

X (formerly, Twitter) - aayushxkhanna

CYBER MONDAY SALE: You can avail InvestingPro+ at a massive 60% discount and by using the coupon code PROC324 get an extra 10% discount over and above the ongoing promotional price for the Annual and Bi-yearly plans. Click on the image below to access the link

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.